Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Spark Therap (ONCE)

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,375,056
  • Shares Outstanding, K 38,523
  • Annual Sales, $ 64,730 K
  • Annual Income, $ -78,820 K
  • 60-Month Beta 2.05
  • Price/Sales 65.92
  • Price/Cash Flow N/A
  • Price/Book 12.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.56
  • Most Recent Earnings -1.67 on 02/19/19
  • Next Earnings Date 11/26/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.47
  • Number of Estimates 3
  • High Estimate -1.13
  • Low Estimate -1.84
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +16.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
109.25 +0.73%
on 12/04/19
113.90 -3.38%
on 12/16/19
-0.76 (-0.69%)
since 11/15/19
3-Month
95.92 +14.73%
on 10/02/19
113.90 -3.38%
on 12/16/19
+5.65 (+5.41%)
since 09/17/19
52-Week
34.53 +218.71%
on 12/26/18
114.20 -3.63%
on 03/12/19
+69.70 (+172.74%)
since 12/17/18

Most Recent Stories

More News
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia's "Best Places to Work" by the Philadelphia Business Journal

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today...

ONCE : 110.05 (-3.10%)
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress

All five participants in the 5x10 vg/kg and 1�?10 vg/kg dose cohorts and seven participants in the 2�?10 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and...

ONCE : 110.05 (-3.10%)
7MM Retinitis Pigmentosa (RP) Market Insights, 2017-2030 - United States, Germany, France, Italy, Spain, United Kingdom, and Japan

, /PRNewswire/ -- The drug pipelines has been added to offering.

NVS : 84.29 (+2.62%)
ONCE : 110.05 (-3.10%)
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine

Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the publication of new research in the journal Nature...

ONCE : 110.05 (-3.10%)
Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases

and , /PRNewswire/ -- announced today that it has raised in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. Kriya was formed in the...

ONCE : 110.05 (-3.10%)
TCR(2) Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors

TCR Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment...

ONCE : 110.05 (-3.10%)
TCRR : 16.88 (+0.78%)
Ophthalmic Drugs Market Size & Share to Drive Huge Growth through 2027

Transparency Market Research (TMR) has published a new report titled, ''. According to the report, the global was valued at in and is projected to expand at a CAGR of from to

AGN : 193.02 (+0.02%)
BAYRY : 16.9200 (+2.69%)
NVS : 84.29 (+2.62%)
PFE : 38.57 (+0.23%)
REGN : 639.99 (+1.25%)
ONCE : 110.05 (-3.10%)
VRX.TO : 30.80 (-3.33%)
Christopher Hite Joins Royalty Pharma

Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman.

BMY : 59.45 (+1.35%)
CELGZ : 0.47 (+2.15%)
GSK : 41.29 (+2.41%)
ONCE : 110.05 (-3.10%)
Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing

With the global market for gene therapy expected to hit $13 billion (USD) by 2024 (Research And Markets), Bioprocessing Summit Europe is returning March 24-26, 2020 with its popular Gene Therapy CMC and...

ONCE : 110.05 (-3.10%)
Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as Companies are Investing More on Research and Development, Says Absolute Markets Insights

In terms of revenue, global gene therapy market was valued at US$ 919.6 million in 2018 and is anticipated to reach US$ 5,609.9 million by 2027, growing at a CAGR of 8.2% over the forecast period. Market...

PFE : 38.57 (+0.23%)
ONCE : 110.05 (-3.10%)
VYGR : 11.24 (+1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ONCE with:

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Key Turning Points

2nd Resistance Point 114.08
1st Resistance Point 113.82
Last Price 110.05
1st Support Level 113.39
2nd Support Level 113.22

See More

52-Week High 114.20
Last Price 110.05
Fibonacci 61.8% 83.77
Fibonacci 50% 74.36
Fibonacci 38.2% 64.96
52-Week Low 34.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar